Article

Impact of human T cell leukemia virus type 1 in living donor liver transplantation.

Department of Surgery and Multidisciplinary Treatment, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
American Journal of Transplantation (Impact Factor: 6.19). 04/2012; 12(6):1479-85. DOI: 10.1111/j.1600-6143.2012.04037.x
Source: PubMed

ABSTRACT Human T cell leukemia virus type 1 (HTLV-1) is an endemic retrovirus in southwestern Japan, which causes adult T cell leukemia (ATL) or HTLV-1 associated myelopathy in a minority of carriers. Here, we investigated the impact of HTLV-1 status in living donor liver transplantation (LDLT). Twenty-six of 329 (7.9%) HTLV-1 carriers underwent primary LDLT. One recipient negative for HTLV-1 before LDLT received a graft from an HTLV-1 positive donor. Eight donors were HTLV-1 positive. Twenty-seven recipients (13 male and 14 female; mean age 52.5 years) were reviewed retrospectively. ATL developed in four recipients who ultimately died. The intervals between LDLT and ATL development ranged from 181 to 1315 days. Of the four ATL recipients, two received grafts from HTLV-1 positive donors and two from negative donors. The 1-, 3- and 5-year HTLV-1 carrier survival rates were 91.3%, 78.3% and 66.3%, respectively. Fulminant hepatic failure as a pretransplant diagnosis and a pretransplant MELD score ≥ 15 was identified as risk factors for ATL development in this study (p = 0.001 and p = 0.041, respectively). In conclusion, LDLT can be performed for HTLV-1 positive recipients. However, when fulminant hepatic failure is diagnosed, LDLT should not be performed until further studies have revealed the mechanisms of ATL development.

0 Bookmarks
 · 
98 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Emerging viral pathogens include newly discovered viruses as well as previously known viruses that are either increasing, or threatening to increase in incidence. While often first identified in the general population, they may affect transplant recipients, in whom their manifestations may be atypical or more severe. Enhanced molecular methods have increased the rate of viral discovery but have not overcome the problem of demonstrating pathogenicity. At the same time, improved clinical diagnostic methods have increased the detection of re-emerging viruses in immunocompromised patients. In this review, we first discuss viral diagnostics and the developing field of viral discovery and then focus on rare and emerging viruses in the transplant population: HTLV-1; HEV; bocavirus; KI and WU polyomaviruses; coronaviruses HKU1 and NL63; influenza, H1N1; measles; dengue; rabies; and LCMV. Detection and reporting of such rare pathogens in transplant recipients is critical to patient care and improving our understanding of post-transplant infections.
    Clinical Infectious Diseases 07/2013; · 9.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Right posterior sector (RPS) grafts have been used to overcome graft-size discrepancy, the major concern in living donor liver transplantation (LDLT). Previous studies reported volumetry-based selection of RPS grafts without anatomical exclusion. We reviewed our data and established selection criteria for RPS grafts. RPS graft procurement (conventional [n=3] and extended RPS grafts [n=5]) was performed for 8 of 429 recipients in our center. Extended RPS grafts contained the drainage area of the right hepatic vein. The mean graft weight (GW) by three-dimensional CT volumetry was 488 g, and the GW-standard liver weight (SLW) ratio was 42.6%. The mean actual GW was 437 g, and the GW-SLW ratio was 38.4%. One donor exhibited standard bifurcation of the right and left portal vein (PV), and two exhibited trifurcation of the left PV and right anterior and posterior PV. The remaining five donors exhibited anterior PV branching from the left PV, the most suitable anatomy for RPS grafts. Two recipients died of sepsis and small-for-size graft syndrome. One underwent re-transplantation owing to intractable bile leak and fibrosing cholestatic hepatitis. Intractable bile duct (BD) stenosis developed in four recipients of the six survivors. In conclusion, with the significant complications and potential concerns associated with the RPS graft, this graft should be used very rarely and with extreme caution. Donors with standard bifurcation of the PV and posterior bile duct running through the dorsal side of the posterior PV are not suitable candidates for RPS grafts. Extended RPS graft procurement is recommended for easier parenchymal transection. Liver Transpl , 2014. © 2014 AASLD.
    Liver Transplantation 06/2014; · 3.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Limit of donor age, graft size and model for end-stage liver disease (MELD) score has not been apparent in living donor liver transplantation (LDLT). Our team has developed the following formula for predicting graft survival after living donor liver transplantation (LDLT): predictive score = 0.011 × graft weight (%) - 0.016 × donor age - 0.008 × MELD score -0.15 × portosystemic shunt (if present) + 1.757. The aim of this study was to re-evaluate the reliability of our formula and to assess whether our modified treatment strategy has improved the 6-month graft survival. Two hundred and seventeen patients were allocated to two groups with predictive scores ≥ 1.30 (n = 162) and < 1.30 (n = 55) and subgroups with scores from 1.15-1.30 (n = 37) or < 1.15 (n = 18). Survival rates in patients scoring < 1.3 were significantly worse than for those scoring ≥ 1.3 (p = 0.006). Survival rates in patients scoring < 1.15 were significantly worse than for those scoring 1.15-1.3 (p < 0.0001). Multivariate analysis showed that predictive scores < 1.15 (odds ratio = 7.87, p=0.006) and BMI ≥ 30 kg/m(2) (odds ratio = 13.3, p=0.0003) were independent risk factors for 6-month graft mortality. In conclusion, predictive scores reliably predict 6-month graft survival, allowing widening of the safe ranges for donor age and graft size. Liver Transpl , 2013. © 2013 AASLD.
    Liver Transplantation 11/2013; · 3.94 Impact Factor

Full-text (2 Sources)

View
2 Downloads
Available from
Oct 20, 2014